SAN ANTONIO--(BUSINESS WIRE)--Aug. 27, 2008--Kinetic Concepts,
Inc. (NYSE: KCI) announced today that it has named Lisa Colleran as
President of its LifeCell business and a member of KCI's Executive
Committee. Colleran previously served as Senior Vice President of
Commercial Operations for LifeCell with responsibility for Sales and
Marketing, surgeon education, new product launches, Business
Development, as well as leading the company's Tissue Services
organization.
"As head of LifeCell's Commercial Operations and a member of its
senior management team, Lisa has been instrumental in the company's
commercial success over the past five years and is well positioned to
successfully lead the next phase of LifeCell's evolution as a KCI
company," said Catherine M. Burzik, KCI's President and CEO. "Lisa
knows our customers and our products and has been a key catalyst in
driving LifeCell's growth. She will be a strong addition to the KCI
Executive Committee. The integration of LifeCell is nearing completion
and we are very pleased with the performance of the regenerative
medicine business since the acquisition. Our AlloDerm(R) and
Strattice(R) products continue to perform well and we are confident
about the future performance and growth opportunities for the LifeCell
business."
Colleran joined LifeCell in 2002 as Vice President of Marketing
and Business Development and was promoted to Senior Vice President of
Commercial Operations in July 2004. Prior to joining LifeCell,
Colleran spent 20 years at Baxter Healthcare Corporation in various
roles of increasing responsibility in Sales, Marketing, Business
Development and general management, including significant
international experience.
"I am really looking forward to leading the LifeCell organization
as part of KCI," said Colleran. "Together we can focus on unlocking
the value of the combined company globally while continuing to build
upon LifeCell's legacy of delivering unparalleled therapeutic
solutions to improve patients' lives around the world."
Colleran replaces Paul Thomas who has resigned from the company.
Burzik added, "I would like to thank Paul Thomas for his
outstanding leadership of LifeCell and his dedication to innovation
and delivering best-in-class technologies. He and his management team
have built a well-respected leader in the tissue regeneration market."
About KCI
Kinetic Concepts, Inc. (NYSE: KCI) is a leading global medical
technology company devoted to the discovery, development, manufacture
and marketing of innovative, high-technology therapies and products
for the wound care, tissue regeneration and therapeutic support system
markets. Headquartered in San Antonio, Texas, KCI's success spans more
than three decades and can be traced to a history deeply rooted in
innovation and a passion for significantly improving the healing - and
the lives - of patients around the world.
KCI's three primary businesses include:
Advanced Wound Care - Includes KCI's proprietary Vacuum Assisted
Closure(R), or V.A.C.(R) Therapy System, which has been clinically
demonstrated to promote wound healing through unique mechanisms of
action while reducing the overall cost of treating patients with
complex wounds.
Regenerative Medicine - Represented by KCI's LifeCell business and
includes tissue-based products for use in reconstructive, orthopedic
and urogynecologic surgical procedures to repair soft tissue defects.
Therapeutic Support Systems - Includes specialty hospital beds,
mattress replacement systems and overlays designed to address
pulmonary complications associated with immobility, to reduce skin
breakdown and assist caregivers in the safe and dignified handling of
patients of size.
The company employs 7,000 people and markets its products in more
than 20 countries. For more information about KCI, and how its
products are changing the practice of medicine, visit www.KCI1.com.
CONTACT:
Kinetic Concepts, Inc.
Media Relations:
Kristie Madara, 210-255-6232
kristie.madara@kci1.com
or
Investor Relations:
Rich Cockrell, 210-255-6331
Rich.cockrell@kci1.com
SOURCE:
Kinetic Concepts, Inc.
